A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 24, Issue 2, 1996, Pages 153-172

  Bruno, René ^a   Vivier, Nicole ^a   Vergniol, Jean Claude ^a   De Phillips, Susan L ^a   Montay, Guy ^a   Sheiner, Lewis B ^b  

^a SANOFI   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

docetaxel; model building; model validation; NONMEM; population pharmacokinetics; Taxotere

Indexed keywords

DOCETAXEL;

ADULT; ARTICLE; DRUG CLEARANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MODEL; PHARMACOKINETICS; POPULATION RESEARCH; PRIORITY JOURNAL;

EID: 0029783171     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02353487     Document Type: Article

References (17)

1. C. C. Peck, W. H. Barr, L. Z. Benet, J. Collins, R. E. Desjardins, D. E. Furst, J. G. Harter, G. Levy, T. Ludden, J. H. Rodman, L. Sanathanan, J. J. Schentag, V. P. Shah, L. B. Sheiner, J. P. Skelly, D. R. Stanski, R. J. Temple, C. T. Viswanashan, J. Weissinger, and A. Yacobi. Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. Clin. Pharmacol. Ther. 51:465-473 (1992).
2. L. Aarons, L. P. Balant, F. Mentré, P. L. Morselli, M. Rowland, J. L. Steimer, and S. Vozeh. Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software. Eur. J. Clin. Pharmacol. 46:389-391 (1994).
3. S. Vozeh, P. O. Maitre, and D. R. Stanski. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J. Pharmacokin. Biopharm. 18:161-173 (1990).
4. S. L. Beal. Validation of a population model. E-mail on the NONMEM Users Network. February 1, 1994.
5. R. Pazdur, A. P. Kudelka, J. J. Kavanagh, P. R. Cohen, and M. N. Raber. The taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®). Cancer Treat. Rev. 19:351-386 (1993).
6. R. Bruno and G. Sanderink. Pharmacokinetics and metabolism of Taxotere™. Cancer Surveys 17:305-313 (1993).
7. R. Bruno, V. Cosson, J. C. Vergniol, G. Montay, N. Le Bail, M. Bayssas, M. Marty, M. Clavel, M. Aapro, P. Alberto, and A. Frydman. Taxotere population pharmacokinetics. Proc. Am. Assoc. Cancer Res. 34:234 (1993) (abstract).
8. M. C. Launay-Iliadis, R. Bruno, V. Cosson, J. C. Vergniol, D. Oulid-Aissa, M. Marty, M. Clavel, M. Aapro, N. Le Bail, and A. Iliadis. Population pharmacokinetics of docetaxel during Phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother. Pharmacol. 37:47-54 (1995).
9. R. Bruno, M. B. Dorr, G. Montay, A. Frydman, F. This, P. Fumoleau, S. Kay, G. H. Kavanagh, H. A. Burris, J. R. Rigas, and M. Bayssas. Design and prospective implementation of population pharmacokinetic studies during the development of docetaxel (RP 56976), a new anticancer drug. Clin. Pharmacol. Ther. 55:161 (1994) (abstract).
10. J. C. Vergniol, R. Bruno, G. Montay, and A. Frydman. Determination of Taxatere in human plasma by a semi-automated high-performance liquid chromatographic method. J. Chromatog. 582:273-278 (1992).
11. S. L. Beal, A. J. Boeckman, and L. B. Sheiner. NONMEM. User's Guide Part I to VI, University of California at San Francisco, San Francisco, 1988-1992.
12. L. B. Sheiner and S. L. Beal. Some suggestions for measuring predictive performance. J. Pharmacokin. Biopharm. 9:503-512 (1981).
13. L. B. Sheiner and L. Z. Benet. Premarketing observational studies of population pharmacokinetics of new drugs. Clin. Pharmacol. Ther. 38:481-487 (1985).
14. P. O. Maitre, M. Bührer, D. Thomson, and D. R. Stanski. A three-step approach combining Bayesian regression and NONMEM population analysis: Application to midazolam. J. Pharmacokin. Biopharm. 19:377-384 (1991).
15. J. W. Mandema, D. Verotta, and L. B. Sheiner. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokin. Biopharm. 20:511-528 (1992).
16. R. Bruno, M.-C. Iliadis, B. Lacarelle, V. Cosson, J. W. Mandema, Y. Le Roux, G. Montay, A. Durand, M. Ballereau, M. Alasia, J. Albanese, G. Francois, A. Iliadis, and A. Frydman. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patients. J. Pharmacokin. Biopharm. 20:653-669 (1992).
17. R. Bruno, D. Hille, L. Thomas, A. Riva, and L. B. Sheiner. Population pharmacokinetics/pharmacodynamics (PK/PD) of docetaxel (Taxotere®) in Phase II studies. Proc. Am. Soc. Clin. Oncol. 14:457 (1995) (abstract).